Drugs / 18F-flurpiridaz
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07284576 | Dec 2025 → Jun 2030 expected | coronary artery disorder, myocardial infarction, myocardial ischemia | Akiva Mintz | Enrolling by invitation | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-flurpiridaz | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07284576 ↗ |
| Modality | Diagnostic / imaging agent | “investigational ultralow dose PET imaging technique” NCT07284576 ↗ |